Practical aspects of treatment discontinuation and adherence

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hypertension control in populations, although improving, remains far from satisfactory, even though effective and inexpensive therapies are available. Among many factors responsible for this situation, poor adherence to treatment appears to be particularly important. Unfortunately, even if its causes have been quite well defined, this problem is still far from being solved in clinical practice. The present paper discusses the key issues related to treatment adherence, and discontinuation in hypertension, in the light of recent evidence coming from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease trial (TRANSCEND).

Original languageEnglish
JournalJournal of Hypertension
Volume27
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2009

Fingerprint

Ramipril
Hypertension
Cardiovascular Diseases
Population
telmisartan
Therapeutics

Keywords

  • Adherence
  • Compliance
  • Discontinuation
  • Hypertension
  • Telmisartan

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Practical aspects of treatment discontinuation and adherence. / Parati, Gianfranco; Bilo, Grzegorz.

In: Journal of Hypertension, Vol. 27, No. SUPPL. 2, 2009.

Research output: Contribution to journalArticle

@article{403f81e54dcd43239f6f6cbbd711d614,
title = "Practical aspects of treatment discontinuation and adherence",
abstract = "Hypertension control in populations, although improving, remains far from satisfactory, even though effective and inexpensive therapies are available. Among many factors responsible for this situation, poor adherence to treatment appears to be particularly important. Unfortunately, even if its causes have been quite well defined, this problem is still far from being solved in clinical practice. The present paper discusses the key issues related to treatment adherence, and discontinuation in hypertension, in the light of recent evidence coming from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease trial (TRANSCEND).",
keywords = "Adherence, Compliance, Discontinuation, Hypertension, Telmisartan",
author = "Gianfranco Parati and Grzegorz Bilo",
year = "2009",
doi = "10.1097/01.hjh.0000354515.36956.67",
language = "English",
volume = "27",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Practical aspects of treatment discontinuation and adherence

AU - Parati, Gianfranco

AU - Bilo, Grzegorz

PY - 2009

Y1 - 2009

N2 - Hypertension control in populations, although improving, remains far from satisfactory, even though effective and inexpensive therapies are available. Among many factors responsible for this situation, poor adherence to treatment appears to be particularly important. Unfortunately, even if its causes have been quite well defined, this problem is still far from being solved in clinical practice. The present paper discusses the key issues related to treatment adherence, and discontinuation in hypertension, in the light of recent evidence coming from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease trial (TRANSCEND).

AB - Hypertension control in populations, although improving, remains far from satisfactory, even though effective and inexpensive therapies are available. Among many factors responsible for this situation, poor adherence to treatment appears to be particularly important. Unfortunately, even if its causes have been quite well defined, this problem is still far from being solved in clinical practice. The present paper discusses the key issues related to treatment adherence, and discontinuation in hypertension, in the light of recent evidence coming from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease trial (TRANSCEND).

KW - Adherence

KW - Compliance

KW - Discontinuation

KW - Hypertension

KW - Telmisartan

UR - http://www.scopus.com/inward/record.url?scp=69449096733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69449096733&partnerID=8YFLogxK

U2 - 10.1097/01.hjh.0000354515.36956.67

DO - 10.1097/01.hjh.0000354515.36956.67

M3 - Article

VL - 27

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - SUPPL. 2

ER -